Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 77 |
| Active Pipeline (Recruiting Now) | 36 (21) |
| Completed vs Stopped Early | 20 / 6 (7.8%) |
| Median Closed Actual Enrollment | 49 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University College London Hospital | London | 14 |
| Churchill Hospital | Oxford | 12 |
| Beatson West of Scotland Cancer Centre | Glasgow | 8 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03288532 | Renal Adjuvant MultiPle Arm Randomised Trial | Phase III | RECRUITING |
| NCT06762769 | Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma | Phase II | RECRUITING |
| NCT06320067 | A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | Phase III | RECRUITING |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinae | Phase II/III | RECRUITING |
| NCT05185739 | Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University College, London Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.